NeurogesX Announces Preliminary Results From Second Phase 3 Clinical Trial In HIV DSP

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced preliminary top-line results from study C119, its second Phase 3 clinical trial of NGX-4010, the Company’s dermal patch drug candidate, in patients with HIV-distal sensory polyneuropathy (HIV-DSP).

More: continued here

Filed under: Pain / Anesthetics on March 3rd, 2008